FDA Race/Ethnicity Data Guide Retains OMB Terms Despite Industry Criticism
FDA's final guidance for collecting and reporting race and ethnicity data in clinical trials retains Office of Management & Budget definitions despite industry concerns about applying the categories abroad
You may also be interested in...
FDA should use global definitions to set categories for collection of race and ethnicity data in clinical trials, the Pharmaceutical Research & Manufacturers of America said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials